Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06158477 | RECRUITING | Advanced Solid Tumors

A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
Sponsor:

Chengdu JOYO pharma Co., Ltd.

Brief Summary:

The goal of this Phase I clinical trial is to evaluate the safety, tolerability, and pharmacokinetic characteristics of the JYP0035 capsule in patients with advanced solid tumors. The main questions it aims to answer are: * What is the safety profile of JYP0035 when administered to these patients? * How does JYP0035 capsule behave in the body pharmacokinetically? Participants will: * Receive escalating doses of JYP0035 capsule during the dose-escalation phase (PART-1). * Continue with the identified dose in the dose-expansion phase (PART-2). As this is a single-arm study, there is no comparison group.

Condition or disease

Advanced Solid Tumors

Intervention/treatment

JYP0035 Experimental Drug Treatment

Phase

PHASE1

Study Type : INTERVENTIONAL
Estimated Enrollment : 75 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : An Open-label Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors
Actual Study Start Date : 2024-01-01
Estimated Primary Completion Date : 2026-12-01
Estimated Study Completion Date : 2027-12-01

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 74 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Patients voluntarily participate in the clinical trial and sign the informed consent form
  • * Age 18 years and above (inclusive), and below 75 years of age (inclusive), with no gender restrictions
  • * ECOG(Eastern Cooperative Oncology Group)performance status of 0 or 1
  • * Expected survival time of ≥3 months
  • * During the screening period, female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to administration of the study drug
  • * Participants agree to use reliable contraception methods from signing the informed consent form until 6 months after the last dose of the study drug. This includes, but is not limited to: abstinence, vasectomy in males, female sterilization, effective intrauterine devices, and effective contraceptive medications
Exclusion Criteria
  • * Participants have not recovered to normal or ≤ Grade 1 from any adverse events and/or complications caused by any previous treatments before the first administration of the study drug, excluding hair loss and pigmentation
  • * Patients with imaging (CT or MRI) showing tumor invasion into major blood vessels (such as the aorta, pulmonary arteries and veins, vena cava, etc.)
  • * Patients who have had clinically significant cardiovascular or cerebrovascular diseases within 6 months before the first administration, which, in the investigator's judgment, may interfere with the patient's full participation in the study; atrial fibrillation; clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention
  • * Patients who had history of type 1 diabetes, type 2 diabetes, or gestational diabetes
  • * Individuals with other malignancies or with a history of other malignant tumors
  • * Individuals with a history of severe allergies, or who are allergic to any active or inactive ingredients of the study drug
  • * Pregnant or breastfeeding patients
  • * Researchers consider participants unsuitable for this clinical study due to any clinical or laboratory abnormalities or other reasons
A Clinical Trial Evaluating JYP0035 Capsule Monotherapy in Patients With Advanced Solid Tumors

Location Details

NCT06158477

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

China, Shanghai Municipality

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China, 311215